All In Biotech

Drug Trial Radar · NCT00365105

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

Jul 11, 2006

Primary completion

Jan 2012

Study completion Feb 27, 2017

Sponsor

Lead sponsor
Radiation Therapy Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); NRG Oncology
First posted
Aug 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.

Conditions

  • Breast Cancer
  • Lung Cancer
  • Metastatic Cancer
  • Pain
  • Prostate Cancer

Interventions

  • CalciumDietary supplement

    At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.

  • Vitamin DDietary supplement

    400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.

  • zoledronic acidDrug

    4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.

  • Sm-153Drug

    Single dose intravenously 1 mCi/kg body weight.

  • Sr-89Radiation

    Single dose intravenously 4 mCi.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Development of a Malignant Skeletal-related Events (SRE)Time frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 80.1 months.

Locations

147 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Center at Providence Hospital

    Mobile, Alabama

  • Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center

    Burbank, California

  • Mercy Cancer Center at Mercy San Juan Medical Center

    Carmichael, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center

    Pomona, California

  • Radiation Oncology Center - Roseville

    Roseville, California

  • Radiological Associates of Sacramento Medical Group, Incorporated

    Sacramento, California

  • General Robert Huyser Cancer Center at David Grant Medical Center

    Travis Air Force Base, California

  • Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital

    Fort Lauderdale, Florida

  • Baptist Cancer Institute - Jacksonville

    Jacksonville, Florida

  • Integrated Community Oncology Network at Southside Cancer Center

    Jacksonville, Florida

  • Baptist Medical Center South

    Jacksonville, Florida

  • Integrated Community Oncology Network

    Jacksonville Beach, Florida

  • Miami Cancer Center at Mercy Hospital

    Miami, Florida

  • CCOP - Mount Sinai Medical Center

    Miami Beach, Florida

  • Integrated Community Oncology Network - Orange Park

    Orange Park, Florida

  • Florida Cancer Center - Palatka

    Palatka, Florida

  • Bay Medical

    Panama City, Florida

  • Flagler Cancer Center

    Saint Augustine, Florida

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

    Tampa, Florida

  • John B. Amos Cancer Center

    Columbus, Georgia

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • Northwest Community Hospital

    Arlington Heights, Illinois

  • Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital

    Downers Grove, Illinois

  • Ingalls Cancer Care Center at Ingalls Memorial Hospital

    Harvey, Illinois

  • Veterans Affairs Medical Center - Hines

    Hines, Illinois

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • Advocate Lutheran General Cancer Care Center

    Park Ridge, Illinois

  • Oncology Hematology Associates of Central Illinois, PC - Peoria

    Peoria, Illinois

  • Cancer Institute at St. John's Hospital

    Springfield, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • Center for Cancer Care at Goshen General Hospital

    Goshen, Indiana

  • Cancer Center at Ball Memorial Hospital

    Muncie, Indiana

  • CCOP - Northern Indiana CR Consortium

    South Bend, Indiana

  • McFarland Clinic, PC

    Ames, Iowa

  • CCOP - Iowa Oncology Research Association

    Des Moines, Iowa

  • John Stoddard Cancer Center at Iowa Methodist Medical Center

    Des Moines, Iowa

  • Medical Oncology and Hematology Associates at John Stoddard Cancer Center

    Des Moines, Iowa

  • Medical Oncology and Hematology Associates at Mercy Cancer Center

    Des Moines, Iowa

  • Mercy Cancer Center at Mercy Medical Center - Des Moines

    Des Moines, Iowa

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.